Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
|
Medicine details |
|
Medicine name | rivaroxaban (Xarelto®) |
Formulation | film-coated tablet |
Reference number | 559 |
Indication | Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack |
Company | Bayer Healthcare Pharmaceuticals |
BNF chapter | Cardiovascular system |
Assessment type | N/A |
Status | Excluded due to NICE appraisal |
Date of issue | 25/11/2011 |
NICE guidance |